Protocol #: 17-044
Status
Recruiting
Description
This research study is studying a drug as a possible treatment for p53 mutant metastatic colorectal cancer. The drug involved in this study is: -Lamivudine
Condition
Colorectal Cancer Metastatic
Interventions
Lamivudine
Phase
Phase 2
Study Type
Interventional
Further Study Details
Primary Outcome:
Overall Response Rate
Secondary Outcome:
Progression Free Survival
Overall Survival
Overall Disease Control Rate
Estimated Enrollment
32
Study Start Date
October 31, 2017
Eligibility
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Health Volunteers: No
Criteria
Massachusetts General Hospital
Information Provided By
Massachusetts General Hospital
Official Title
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
Clinicaltrials.gov Identifier
NCT03144804

 

 

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.

Back to Top